A preclinical study in mice suggests that blocking a major inflammatory pathway that is activated in pancreatic cancer makes tumors vulnerable to chemotherapy and a type of immunotherapy that stimulates the immune system's T cells to attack the cancer cells. The therapy more than doubled survival in a mouse pancreatic cancer model.
Pancreatic cancer is one of the most aggressive and deadly types of cancer, known to be resistant to virtually all treatments, including newer immunotherapies.
The study results, published in the journal Gastroenterology , provide additional support for the rationale for a new US national clinical trial that will evaluate the same treatment strategy in adenocarcinoma patients ductal pancreas - the most common malignant neoplasm of the pancreas. Scientists plan to register about 50 patients nationwide.
University of Washington researchers at the Siteman Cance...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
